Dr. Thomas L. Johnson II, M.D.
Allergy & Immunology (Allergy & Immunology Physician)
- Medicare participating
At a glance
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 721
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Allergy & Immunology Physician primary
FL license ME101774
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Medicare patients and services
- Medicare patients, 2024
- 721
- Services billed
- 42,774
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Test for allergy using allergenic extract | 22,411 | 333 |
| Injection, omalizumab, 5 mg | 10,398 | 33 |
| Test for allergy using skin patch | 4,013 | 57 |
| Professional service for multiple injections of allergen | 2,370 | 316 |
| Professional service for preparation and provision of 1 or more antigens | 2,280 | 151 |
| Professional service for single injection of allergen | 1,250 | 95 |
| Injection of drug or substance under skin or into muscle | 642 | 70 |
| Established patient office or other outpatient visit, 30-39 minutes | 513 | 417 |
| New patient office or other outpatient visit, 45-59 minutes | 391 | 391 |
| Administration and interpretation of patient-focused health risk assessment | 358 | 309 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Montelukast Sodium Other prescribers in Gainesville, FL | 172 |
| Levocetirizine Dihydrochloride Other prescribers in Gainesville, FL | 164 |
| Ipratropium Bromide Other prescribers in Gainesville, FL | 111 |
| Fluticasone Propionate Other prescribers in Gainesville, FL | 102 |
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in Gainesville, FL | 96 |
| Trelegy Ellipta (fluticasone/umeclidin/vilanter) Other prescribers in Gainesville, FL | 92 |
| Dupixent Syringe (dupilumab) Other prescribers in Gainesville, FL | 59 |
| Epinephrine Other prescribers in Gainesville, FL | 57 |
| Arnuity Ellipta (fluticasone furoate) Other prescribers in Gainesville, FL | 52 |
| Breo Ellipta (fluticasone/vilanterol) Other prescribers in Gainesville, FL | 42 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 10 companies reported 26 payments worth $12,261 in total to this clinician.
| AstraZeneca Pharmaceuticals LP | $11,995 |
|---|---|
| Regeneron Healthcare Solutions, Inc. | $75.40 |
| Csl Behring | $42.69 |
| Takeda Pharmaceuticals U.S.A., Inc. | $29.38 |
| Pfizer Inc. | $24.97 |
| Ars Pharmaceuticals Operations, Inc. | $21.86 |
| Grifols USA, LLC | $19.80 |
| Greer Laboratories, Inc. | $18.99 |
| Compensation for services other than consulting (speaking, faculty) | $11,150 |
|---|---|
| Food and Beverage | $608 |
| Travel and Lodging | $503 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP Feb 10, 2025 | Compensation for services other than consulting (speaking, faculty) AIRSUPRA · Respiratory Company’s descriptionSpeaker Fee | $3,700 |
| AstraZeneca Pharmaceuticals LP Jan 29, 2025 | Compensation for services other than consulting (speaking, faculty) AIRSUPRA · Respiratory Company’s descriptionSpeaker Fee | $2,800 |
| AstraZeneca Pharmaceuticals LP Mar 24, 2025 | Compensation for services other than consulting (speaking, faculty) AIRSUPRA · Respiratory Company’s descriptionSpeaker Fee | $2,350 |
| AstraZeneca Pharmaceuticals LP Mar 18, 2025 | Compensation for services other than consulting (speaking, faculty) AIRSUPRA · Respiratory Company’s descriptionSpeaker Fee | $1,850 |
| AstraZeneca Pharmaceuticals LP Feb 18, 2025 | Compensation for services other than consulting (speaking, faculty) AIRSUPRA · Respiratory Company’s descriptionSpeaker Fee | $450 |
| AstraZeneca Pharmaceuticals LP Feb 4, 2025 | Travel and Lodging AIRSUPRA · Respiratory · travel to Savannah, GA · in-kind Company’s descriptionSpeaker Expenses | $340 |
| AstraZeneca Pharmaceuticals LP Mar 13, 2025 | Travel and Lodging AIRSUPRA · Respiratory · travel to Lake Mary, FL · in-kind Company’s descriptionSpeaker Expenses | $96.60 |
| AstraZeneca Pharmaceuticals LP Jan 23, 2025 | Travel and Lodging AIRSUPRA · Respiratory · travel to Mount Dora, FL · in-kind Company’s descriptionSpeaker Expenses | $65.80 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $7,272 in research payments for these studies, mostly to the institutions running them.
- Ph iii study to evaluate the efficacy and safety of astegolimab in copd
Genentech, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.